


PATENT
2543-1-030



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Gordon Duane HOLT et al.

SERIAL NO.: 10/601,837

EXAMINER: Unknown

DATE FILED: June 23, 2003

ART UNIT: 1645

FOR: PROTEINS, GENES AND THEIR USE FOR DIAGNOSIS AND
TREATMENT OF KIDNEY DISEASE

CERTIFICATE OF MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner For Patents, P.O. Box 1450, Alexandria, VA on October 15, 2003.

Karen Garipoli
(Name of depositor)


(Signature and Date)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR §1.97 and MPEP 717.05(b), Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The publications forwarded herewith are listed on the enclosed Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed materials, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.


Enclosed please find copies of References **BA** through **CF** listed on the attached Form PTO-1449. No fee is believed due for the filing of this statement inasmuch as it is being filed before the mailing of the first official action on the merits. However, should the Patent and Trademark Office determine otherwise, authorization is hereby given to charge Deposit Account No. 11-1153 for this filing.

Respectfully submitted,


David A. Jackson
Attorney for Applicants
Registration No. 26,742

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, New Jersey 07601
(201) 487-5800

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO.	2543-1-030
		SERIAL NO.	10/601,837
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT	Gordon Duane HOLT et al.
		FILING DATE	June 23, 2003
		GROUP	1645



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS S	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUB-CLASS	TRANSLATION YES NO
	BA	WO 99/47925	9/23/99	PCT			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Kennedy, S., Proteomic profiling from human samples: the body fluid alternative, Toxicology Letters 120 (2001), Pgs. 379-384.		
CB	Cutler, P., et al., An integrated proteomic approach to studying glomerular nephrotoxicity, Electrophoresis (1999), 20, Pgs. 3647-3658.		
CC	Witzmann, F., et al., Regional protein alterations in rat kidneys induced by lead exposure, Electrophoresis (1999), 20, Pgs. 943-951.		
CD	Kanitz, M.H., et al., Alterations in rabbit kidney protein expression following lead exposure as analyzed by two-dimensional gel electrophoresis, Electrophoresis (1999), 20, Pgs. 2977-2985.		
CE	Ho, Y-W., et al., Activation and Inhibition of Human Alcohol Dehydrogenase by Monoclonal Antibodies, Biochimica et Biophysica Acta (1991), 1074, Pgs. 419-423		
CF	Manabe, T., et al., A nondenaturing protein map of human plasma proteins correlated with a denaturing polypeptide map combining techniques of micro two-dimensional gel electrophoresis, Electrophoresis (1999), 20, Pgs. 830-835.		
EXAMINER:		DATE CONSIDERED:	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			